Pages that link to "Q46093084"
Jump to navigation
Jump to search
The following pages link to Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients (Q46093084):
Displaying 50 items.
- Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors (Q24306212) (← links)
- Immunological Evasion in Glioblastoma (Q26746612) (← links)
- Myeloid-Derived Suppressor Cells in Bacterial Infections (Q26749373) (← links)
- Cancer-Associated Myeloid Regulatory Cells (Q26750382) (← links)
- Current status of immunotherapy (Q26773314) (← links)
- Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages (Q26783748) (← links)
- CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma (Q26800814) (← links)
- Myeloid suppressor cells and immune modulation in lung cancer (Q26823251) (← links)
- Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities (Q26852437) (← links)
- Role of immunotherapy for renal cell cancer in 2011 (Q26853453) (← links)
- Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer (Q26861293) (← links)
- Therapeutic cancer vaccines: past, present, and future (Q26863283) (← links)
- Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer (Q26863418) (← links)
- From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors (Q26865532) (← links)
- PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence (Q26865789) (← links)
- Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy (Q26991589) (← links)
- Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes (Q26991991) (← links)
- Reciprocal relationship between myeloid-derived suppressor cells and T cells (Q27000664) (← links)
- Control of the immune response by pro-angiogenic factors (Q27004733) (← links)
- Update on the challenges and recent advances in cancer immunotherapy (Q27014693) (← links)
- Circulating biomarkers in advanced renal cell carcinoma: clinical applications (Q27023770) (← links)
- Recent advances in therapeutic cancer vaccines (Q27025266) (← links)
- Targeting the tumor vasculature to enhance T cell activity (Q27026329) (← links)
- Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy (Q27686800) (← links)
- Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer (Q28066486) (← links)
- Sunitinib: the antiangiogenic effects and beyond (Q28066499) (← links)
- Improving cancer immunotherapy by targeting the STATe of MDSCs (Q28066797) (← links)
- Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience (Q28068959) (← links)
- Sunitinib in the treatment of metastatic renal cell carcinoma (Q28072057) (← links)
- Medical treatment of renal cancer: new horizons (Q28073174) (← links)
- Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets (Q28076161) (← links)
- The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression (Q28076760) (← links)
- Phenotype, development, and biological function of myeloid-derived suppressor cells (Q28079046) (← links)
- Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy (Q28080262) (← links)
- Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy (Q28082461) (← links)
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected (Q28084627) (← links)
- Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now? (Q28301672) (← links)
- ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis (Q28386923) (← links)
- Myeloid-derived cells are key targets of tumor immunotherapy (Q28388246) (← links)
- Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies (Q28393381) (← links)
- Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics (Q28393614) (← links)
- Coordinated regulation of myeloid cells by tumours (Q28395157) (← links)
- Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer (Q28481476) (← links)
- Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases (Q28727917) (← links)
- STATs in cancer inflammation and immunity: a leading role for STAT3 (Q29547203) (← links)
- The immune contexture in human tumours: impact on clinical outcome (Q29620667) (← links)
- Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors (Q30317831) (← links)
- Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia (Q30399006) (← links)
- Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma (Q30429380) (← links)
- Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines (Q31085777) (← links)